BISOPROLOL FUMARATE | A075643 | RUBICON RESEARCH LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consultant Services, Inc. FDA-2007-P-0177 · 7 docket documents Lachman Consultant Services, Inc. filed this citizen petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Bisoprolol Fumarate and Hydrochlorothiazide Tablets in strengths of 5 mg/12.5 mg, 10 mg/12.5 mg, and 20 mg/12.5 mg suitable for submissi | Other | 2008-05-06 | Partially Denied | Lachman Consultant Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$2.61
per ea
Lowest NADAC/Unit
$0.1333
per ea
Brand NDCs
0
Generic NDCs
5
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 52817026830BISOPROLOL FUMARATE 2.5 MG TAB | $2.61 | EA | Generic | — | 2026-06-17 |
| 72888009301BISOPROLOL FUMARATE 10 MG TAB | $0.1955 | EA | Generic | — | 2026-06-17 |
| 72888009330BISOPROLOL FUMARATE 10 MG TAB | $0.1955 | EA | Generic | — | 2026-06-17 |
| 72888009201BISOPROLOL FUMARATE 5 MG TAB | $0.1333 | EA | Generic | — | 2026-06-17 |
| 72888009230BISOPROLOL FUMARATE 5 MG TAB | $0.1333 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.